Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24087029 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Susana Rojo-Tolosa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Medicine Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Hypersensitivity. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Biobank of the Hospital Universitario Virgen de las Nieves.
Abstract (Originalsprache)
Omalizumab is a monoclonal antibody indicated for the treatment of severe uncontrolled asthma with an allergic phenotype. Its effectiveness could be influenced by clinical variables and single nucleotide polymorphisms (SNPs) in one or more of the genes involved in the mechanism of action and process of response to omalizumab, and these could be used as predictive biomarkers of response. We conducted an observational retrospective cohort study that included patients with severe uncontrolled allergic asthma treated with omalizumab in a tertiary hospital. Satisfactory response after 12 months of treatment was defined as (1) Reduction ≥ 50% of exacerbations or no exacerbations, (2) Improvement of lung function ≥ 10% FEV1, and (3) Reduction ≥ 50% of OCS courses or no OCS. Polymorphisms in the FCER1A (rs2251746, rs2427837), FCER1B (rs1441586, rs573790, rs1054485, rs569108), C3 (rs2230199), FCGR2A (rs1801274), FCGR2B (rs3219018, rs1050501), FCGR3A (rs10127939, rs396991), IL1RL1 (rs1420101, rs17026974, rs1921622), and GATA2 (rs4857855) genes were analyzed by real-time polymerase chain reaction (PCR) using TaqMan probes. A total of 110 patients under treatment with omalizumab were recruited. After 12 months of treatment, the variables associated with a reduction in exacerbations were the absence of polyposis (odds ratio [OR] = 4.22; 95% confidence interval [CI] = 0.95–19.63), IL1RL1 rs17026974-AG (OR = 19.07; 95% CI = 1.27–547), and IL1RL1 rs17026974-GG (OR = 16.76; 95% CI = 1.22–438.76). Reduction in oral corticosteroids (OCS) was associated with age of starting omalizumab treatment (OR = 0.95; 95% CI = 0.91–0.99) and blood eosinophil levels > 300 cells/µL (OR = 2.93; 95% CI = 1.01–9.29). Improved lung function showed a relationship to the absence of chronic obstructive pulmonary disease (COPD) (OR = 12.16; 95% CI = 2.45–79.49), FCGR2B rs3219018-C (OR = 8.6; 95% CI = 1.12–117.15), GATA2 rs4857855-T (OR = 15.98; 95% CI = 1.52–519.57) and FCGR2A rs1801274-G (OR = 13.75; 95% CI = 2.14–142.68; AG vs. AA and OR = 7.46; 95% CI = 0.94–89.12; GG vs. AA). Meeting one response criterion was related to FCER1A rs2251746-TT (OR = 24; 95% CI = 0.77–804.57), meeting two to age of asthma diagnosis (OR = 0.93; 95% CI = 0.88–0.99), and meeting all three to body mass index (BMI) < 25 (OR = 14.23; 95% CI = 3.31–100.77) and C3 rs2230199-C (OR = 3; 95% CI = 1.01–9.92). The results of this study show the possible influence of the polymorphisms studied on the response to omalizumab and the clinical benefit that could be obtained by defining predictive biomarkers of treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Respiratory Medicine Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
- Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
- Center of Biomedical Research, Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology "José Mataix", University of Granada, Avda. del Conocimiento s/n., 18016 Granada, Spain.
- Cancer Registry of Granada, Andalusian School of Public Health, Carretera del Observatorio, 4, 18011 Granada, Spain.
ORCID-Profile: Susana Rojo-Tolosa, Laura Elena Pineda-Lancheros, José María Gálvez-Navas
Förderung
- Instituto de Salud Carlos III
- Biobank of the Hospital Universitario Virgen de las Nieves
Zitieren
APA
Rojo-Tolosa, S., Sánchez-Martínez, J. A., Pineda-Lancheros, L. E., Gálvez-Navas, J. M., González-Gutiérrez, M. V., Jiménez-Gálvez, G., Pérez-Ramírez, C., Morales-García, C., & Jiménez-Morales, A. (2023). Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087029
Vancouver
Rojo-Tolosa S, Sánchez-Martínez JA, Pineda-Lancheros LE, Gálvez-Navas JM, González-Gutiérrez MV, Jiménez-Gálvez G, et al. Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087029
BibTeX
@article{RojoTolosa2023,
author = {Rojo-Tolosa, Susana and Sánchez-Martínez, José Antonio and Pineda-Lancheros, Laura Elena and Gálvez-Navas, José María and González-Gutiérrez, María Victoria and Jiménez-Gálvez, Gonzalo and Pérez-Ramírez, Cristina and Morales-García, Concepción and Jiménez-Morales, Alberto},
title = {Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24087029}
}
EUVIMED